natgillin/translations-raw huggingface dataset:
The antiplatelet effect may theoretically be altered and should be carefully monitored when cilostazol is co-administered with CYP3A4 and CYP2C19 inducers.
Antiagregacijski učinek se lahko teoretično spremeni in ga je treba skrbno spremljati pri sočasnem dajanju cilostazola z induktorji CYP3A4 in CYP2C19.
<Cilostazol-containing medicinal product> is for second-line use, in patients in whom lifestyle modifications (including stopping smoking and [supervised] exercise programs) and other appropriate interventions have failed to sufficiently improve their intermittent claudication symptoms.
<Zdravilo, ki vsebuje cilostazol> je za uporabo kot druga izbira zdravljenja pri bolnikih, pri katerih sprememba življenjskega sloga (vključno s prenehanjem kajenja in [nadziranimi] programi vadbe) in drugi ustrezni posegi niso ustrezno izboljšali njihovih simptomov intermitentne klavdikacije.
The Cmax of cilostazol and its primary circulating metabolites increase less than proportionally with increasing doses.
Cmax za cilostazol in njegove primarne presnovke v obtoku se je z večanjem odmerka povečal manj kot sorazmerno.
increases in mean ACD ranged from 60.4 - 129.1 metres, whilst mean ICD increases ranged from 47.3 - 93.6 metres.
Po 24 tednih zdravljenja je cilostazol 100 mg dvakrat na dan zvišal povprečni razpon ACD med 60,4 do 129,1 metri, povprečni razpon ICD pa se je povečal za med 47,3 do 93,6 metri.
Most patients recovered on discontinuation of cilostazol.
Večina bolnikov je po prekinitvi uporabe cilostazola okrevala.
There have been rare or very rare reports of haematological abnormalities including thrombocytopenia, leucopenia, agranulocytosis, pancytopenia and aplastic anaemia (see section 4.8).
Obstajajo redka ali zelo redka poročila o hematoloških nepravilnostih, vključno s trombocitopenijo, levkopenijo, agranulocitozo, pancitopenijo in aplastično anemijo (glejte poglavje 4.8).
The usual dose is two 50 mg tablets twice a day (morning and evening).
• Priporočeni odmerek je dve tableti 50 mg dvakrat na dan (zjutraj in zvečer).
If you have any further questions, please ask your doctor or your pharmacist.
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali farmacevtom.
WHAT <CILOSTAZOL-CONTAINING MEDICINAL PRODUCT> IS AND WHAT IT IS USED FOR
Kaj je <zdravilo, ki vsebuje cilostazol>, in za kaj ga uporabljamo
However, your doctor may prescribe a lower dose if you are taking other medicines which may have an effect on <Cilostazol-containing medicinal product>.
Vendar pa vam lahko zdravnik predpiše manjši odmerek, če jemljete druga zdravila, ki lahko vplivajo na učinek <zdravila, ki vsebuje cilostazol>.
Based on its mechanism of action, cilostazol may induce tachycardia, palpitation, tachyarrhythmia and/or hypotension.
Na podlagi mehanizma delovanja lahko cilostazol povzroči tahikardijo, palpitacije, tahiaritmijo in/ali hipotenzijo.
However, the AUC for cilostazol and its metabolites increase approximately proportionately with dose.
Vendar pa se AUC za cilostazol in njegove presnovke poveča približno sorazmerno z odmerkom.
Driving and using machines <Cilostazol-containing medicinal product> may cause dizziness.
Vpliv na sposobnost upravljanja vozil in strojev <Zdravilo, ki vsebuje cilostazol>, lahko povzroči omotico.
Caution is needed when co-administering cilostazol with any other agent which has the potential to reduce blood pressure due to the possibility that there may be an additive hypotensive effect with a reflex tachycardia.
Previdnost je potrebna pri sočasni uporabi cilostazola z drugimi zdravili, ki lahko zmanjšajo krvni tlak, saj obstaja možnost aditivnega hipotenzivnega učinka z refleksno tahikardijo.
The usual dose is one 100 mg tablet twice a day (morning and evening).
• Priporočeni odmerek je ena tableta 100 mg dvakrat na dan (zjutraj in zvečer).
What <Cilostazol-containing medicinal product> is and what it is used for Before you take <Cilostazol-containing medicinal product> How to take <Cilostazol-containing medicinal product> Possible side effects
Kaj je <zdravilo, ki vsebuje cilostazol>, in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli <zdravilo, ki vsebuje cilostazol> Kako jemati <zdravilo, ki vsebuje cilostazol> Možni neželeni učinki
An increase in the frequency of diarrhoea and palpitation has been found in patients older than 70 years.
Pri bolnikih, starejših kot 70 let, so opazili povečanje pogostnosti driske in palpitacij.
A meta-analysis based on weighted mean differences across the nine studies indicated that there was a significant absolute overall post-baseline improvement of 42 m in maximal walking distance (ACD) for cilostazol 100 mg b.i.d.
Metaanaliza na podlagi uteženih povprečnih razlik v devetih študijah je pokazala obstoj značilnega absolutnega splošnega izboljšanja po izhodišču 42 m pri najdaljši prehojeni razdalji (ACD) za cilostazol 100 mg dvakrat na dan glede na izboljšanje s placebom.
The effect of CYP3A4 and CYP2C19 inducers (such as carbamazepine, phenytoin, rifampicin and St. John's wort) on cilostazol pharmacokinetics has not been evaluated.
Učinka induktorjev CYP3A4 in CYP2C19 (kot so karbamazepin, fenitoin, rifampicin in šentjanževka) na farmakokinetiko cilostazol niso ovrednotili.
• calcium channel blockers (e.g., verapamil, amlodipine)
• zaviralce kalcijevih kanalčkov (npr. verapamil, amlodipin)
The dehydro metabolite is 4-7 times as active a platelet antiaggregant as the parent compound and the 4'-trans-hydroxy metabolite is one fifth as active.
Presnovek dehidro je 4-7-krat tako aktiven zaviralec agregacije trombocitov kot osnovna spojina, presnovek 4'trans-hidroksi pa je eno petino tako aktiven.
Short term (4 days) co-administration of ASA with cilostazol suggested a 23-25% increase in inhibition of ADP-induced ex vivo platelet aggregation when compared to ASA alone.
Kratkotrajno ( 4 dni) sočasno dajanje ASK s cilostazolom je pokazalo 23-25 % zvišanje zaviranja agregacije trombocitov ex vivo zaradi ADP v primerjavi s samo ASK.
Taking <Cilostazol-containing medicinal product> with food and drink <Cilostazol-containing medicinal product> tablets should be taken 30 minutes before breakfast and the evening meal.
<Zdravilo, ki vsebuje cilostazol>, skupaj s hrano in pijačo <Zdravilo, ki vsebuje cilostazol>, tablete, morate vzeti 30 minut pred zajtrkom in večerjo.
No unusual neoplastic outcomes were observed in two-year carcinogenicity studies in rats at oral (dietary) doses up to 500 mg/kg/day, and in mice at doses up to 1000 mg/kg/day.
V dveletnih študijah kancerogenosti pri podganah s peroralnimi (s hrano) odmerki do 500 mg/kg/dan in pri miših z odmerki do 1.000 mg/kg/dan niso opazili neobičajnih neoplastičnih izidov.
Caution should be exercised when prescribing cilostazol for patients with atrial or ventricular ectopy and patients with atrial fibrillation or flutter.
Pri predpisovanju cilostazola bolnikom z atrijsko ali ventrikularno ektopijo in bolnikom z atrijsko fibrilacijo ali undulacijo je potrebna previdnost.
Therefore, drugs inhibiting CYP3A4 (e.g., some macrolides, azole antifungals, protease inhibitors) or CYP2C19 (like proton pump inhibitors, PPIs) increase the total pharmacological activity and could have the potential to enhance the undesirable effects of cilostazol.
Zato zdravila, ki zavirajo CYP3A4 (npr. nekateri makrolidi, azolni antimikotiki, zaviralci proteaze) ali CYP2C19 (kot so zaviralci protonske črpalke) povečajo skupno farmakološko aktivnost in lahko pospešijo neželene učinke cilostazola.
Like all medicines, <Cilostazol-containing medicinal product> can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi to zdravilo neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
The Cmax and AUC of the dehydro metabolite were 41% and 47% lower respectively in the severely renally impaired subjects compared to subjects with normal renal function.
Cmax in AUC presnovka dehidro sta bila 41 % oz. 47 % nižja pri osebah s hudo okvaro ledvic kot pri osebah normalnim delovanjem ledvic.
The medicine must not be administered to patients with a creatinine clearance <25ml/min (see section 4.3).
Bolniki s očistkom kreatinina < 25 ml/min zdravila ne smejo jemati (glejte poglavje 4.3).
In the case of patients receiving strong inhibitors for CYP3A4 or CYP2C19, plasma levels of cilostazol were shown to be increased.
Pokazalo se je, da se pri bolnikih, ki prejemajo močne zaviralce encimov CYP3A4 ali CYP2C19, ravni cilostazola v plazmi zvišajo.
At lower dose levels, retardations of ossification were observed.
Pri nižjih odmerkih so opazili zapoznelo okostenitev.
<Cilostazol-containing medicinal product> may do the same to other medicines.
Tudi <zdravilo, ki vsebuje cilostazol>, ima lahko enak učinek na nekatera zdravila.
Since cilostazol is extensively metabolised by hepatic enzymes, it is contraindicated in patients with moderate or severe hepatic impairment.
Ker cilostazol obširno presnovijo jetrni encimi, je kontraindiciran pri bolnikih z zmerno ali hudo okvaro jeter.
How to store <Cilostazol-containing medicinal product> Contents of the pack and other information
Shranjevanje <zdravila, ki vsebuje cilostazol> Vsebina pakiranja in dodatne informacije
The primary isoenzymes involved in its metabolism are cytochrome P-450 CYP3A4, to a lesser extent, CYP2C19, and to an even lesser extent CYP1A2.
Primarni izoencimi, ki sodelujejo pri presnovi, so citokrom P-450 CYP3A4, v manjšem obsegu CYP2C19 in v še manjšem obsegu CYP1A2.
A full blood count should be performed if infection is suspected or there is any other clinical evidence of blood dyscrasia.
Pri sumu na okužbo ali drugih kliničnih znakih diskrazije krvi je treba opraviti preiskavo celotne krvne slike.
Cilostazol is not a substitute for such treatments.
Cilostazol ni nadomestilo za ta zdravljenja.
Caution is advised in case of co-administration with statins metabolised by CYP3A4, for example simvastatin, atorvastatin and lovastatin.
Previdnost se priporoča tudi pri sočasnem dajanju s statini, ki jih presnavlja CYP3A4, na primer s simvastatinom, atorvastatinom in lovastatinom.
Cilostazol also inhibits smooth muscle cell proliferation in rat and human smooth muscle cells in vitro, and inhibits the platelet release reaction of platelet-derived growth factor and PF-4 in human platelets.
Cilostazol pri podganah in v celicah gladkih mišic človeka in vitro zavira tudi proliferacijo gladkih mišičnih celic in zavira reakcijo sproščanja trombocitov trombocitnega rastnega faktorja in PF-4 pri trombocitih pri ljudeh.
<Cilostazol-containing medicinal product> tablets should be taken 30 minutes before breakfast and the evening meal.
• <Zdravilo, ki vsebuje cilostazol>, tablete, morate vzeti 30 minut pred zajtrkom in večerjo.
Consequently, for patients concomitantly taking strong CYP3A4 or CYP2C19 inhibitors the recommended dose is 50 mg twice daily (see section
Posledično je za bolnike, ki sočasno jemljejo močne zaviralce CYP3A4 ali CYP2C19, priporočeni odmerek 50 mg dvakrat na dan (glejte poglavje 4.2).
Cilostazol has been shown to increase the AUC of lovastatin (sensitive substrate for CYP3A4) and its hydroxy acid by 70%.
Pokazalo se je, da cilostazol poveča AUC lovastatina (občutljivi substrat CYP3A4) in njegove hidroksi kisline za 70 %.
• beta blockers (e.g., labetalol, carvedilol);
• zaviralce beta (npr. labetalol, karvedilol)
Cilostazol is extensively metabolised by CYP enzymes, particularly CYP3A4 and CYP2C19 and to a lesser extent CYP1A2.
Cilostazol obsežno presnavljajo encimi CYP, zlasti CYP3A4 in CYP2C19, v manjši meri pa CYP1A2.
What <Cilostazol-containing medicinal product> looks like and contents of the pack The <Cilostazol-containing medicinal product> 50 mg tablet is a white, round, flat-faced tablet, debossed with “OG31” on one side.
Izgled <zdravila, ki vsebuje cilostazol>, in vsebina pakiranja <Zdravilo, ki vsebuje cilostazol,> 50 mg tablete, so bele, okrogle, ploske tablete z vtisom "OG31" na eni strani.
The Cmax and AUC of 4'-transhydroxy cilostazol were 173% and 209% greater in subjects with severe renal impairment.
Cmax in AUC 4'-trans-hidroksi cilostazola sta bila 173 % oz. 209 % višja pri osebah s hudo okvaro delovanja ledvic.
Based on these data, the recommended dose of cilostazol is 50 mg bid in the presence of ketoconazole and similar agents (e.g., itraconazole).
Na podlagi teh podatkov je priporočeni odmerek cilostazola 50 mg dvakrat na dan v prisotnosti ketokonazola in podobnih učinkovin (npr. itrokonazola).
Patients with a history of severe tachyarrhythmia Patients treated concomitantly with two or more additional antiplatelet or anticoagulant agents (e.g. acetylsalicylic acid, clopidogrel, heparin, warfarin, acenocoumarol, dabigatran, rivaroxaban or apixaban)
• bolniki, ki se sočasno zdravijo z dvema ali več dodatnimi protitrombocitnimi ali antikoagulantnimi zdravili (npr. acetilsalicilna kislina, klopidogrel, heparin, varfarin,
Acetylsalicylic Acid (ASA)
Acetilsalicilna kislina (ASK)
Based on these data, the recommended dose of cilostazol is 50 mg bid in the presence of erythromycin and similar agents (e.g., clarithromycin).
Na podlagi teh podatkov je priporočeni odmerek cilostazola 50 mg dvakrat na dan v prisotnosti eritromicina in podobnih učinkovin (npr. klaritromicina).
• anticoagulant medicines (e.g. warfarin, dabigatran, rivaroxaban, apixaban or low molecular weight heparins).
• antikoagulante (npr. varfarin, dabigatran, rivaroksaban, apiksaban ali nizkomolekularne heparine).
Before you start taking <Cilostazol-containing medicinal product>, please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Druga zdravila in <zdravilo, ki vsebuje cilostazol> Obvestite svojega zdravnika ali farmacevta, če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katero koli drugo zdravilo.
They may either increase the side effects of <Cilostazol-containing medicinal product> or make <Cilostazol-containing medicinal product> less effective.
Neželene učinke <zdravila, ki vsebuje cilostazol>, lahko povečajo, ali zmanjšajo učinkovitost zdravila, ki vsebuje cilostazol.
The frequencies correspond with: Very common (≥1/10) Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to <1/100) Rare
zelo pogosti (≥1/10) pogosti
The dehydro metabolite, which has 4-7 times the potency of cilostazol in inhibiting platelet aggregation, appears to be formed primarily via CYP3A4.
Kaže, da nastaja presnovek dehidro, ki ima 4-7-kratno jakost cilostazola pri zaviranju agregacije trombocitov, pretežno s CYP3A4.
Cilostazol should be discontinued promptly if there is clinical or laboratory evidence of haematological abnormalities.
Pri kliničnih ali laboratorijskih dokazih hematoloških nepravilnosti je treba z uporabo cilostazola takoj prenehati.
Congestive heart failure
• kongestivno srčno popuščanje
Cilostazol did not alter fertility in animal studies.
V študijah pri živalih cilostazol ni vplival na plodnost.
Cilostazol is contraindicated in patients with a creatinine clearance of  25 ml/min.
Cilostazol je kontraindiciran pri bolnikih z očistkom kreatinina  25 ml/min.
Uric acid level increased, blood urea increased, blood creatinine increased
Preiskave neznana zvišanje ravni sečne kisline, zvišanje sečnine v krvi, zvišanje kreatinina v krvi
• ACE inhibitors (e.g., captopril, lisinopril)
• zaviralce ACE (npr. kaptopril, lizinopril)
The 4`-trans-hydroxy metabolite, with potency one-fifth that of cilostazol, appears to be formed primarily via CYP2C19.
Kaže, da nastaja presnovek 4`-trans-hidroksi, ki ima eno petino jakosti cilostazola, pretežno s CYP2C19.
Certain medicines may interfere with the effect of <Cilostazol-containing medicinal product> when taken together.
Nekatera zdravila lahko ob sočasni uporabi vplivajo na učinek <zdravila, ki vsebuje cilostazol>.
Cilostazol per se may carry an increased risk of bleeding and this risk may be potentiated by coadministration with any other agent with such potential.
Cilostazol sam po sebi lahko pomeni večje tveganje za krvavitev, to tveganje pa lahko sočasna uporaba drugih zdravil z enakim učinkom še poveča.
There may be a higher risk of bleeding into the eye in people with diabetes.
Pri bolnikih s sladkorno boleznijo je lahko tveganje krvavitve v oko povečano.
The stomach should be emptied by induced vomiting or gastric lavage, as appropriate.
Po potrebi jim je treba izprazniti želodec z izzvanim bruhanjem ali izpiranjem želodca.
The following side effects have been reported during the use of <Cilostazol-containing medicinal product> but it is not known how frequently they may occur:
Med uporabo <zdravila, ki vsebuje cilostazol>, so poročali o naslednjih neželenih učinkih z neznano pogostnostjo:
Pregnancy and breast-feeding <Cilostazol-containing medicinal product> MUST NOT be used during pregnancy.
<Zdravila, ki vsebuje cilostazol>, NE SMETE jemati med nosečnostjo.
Eczema, skin eruptions, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria
Bolezni kože in podkožja pogosti izpuščaj, pruritus neznana ekcem, kožni izpuščaji, Stevens-Johnsonov sindrom, toksična epidermalna nekroliza, urtikarija
stroke heart attack heart problems which can cause shortness of breath or ankle swelling irregular heart beat (new or worsening)
• težave s srcem, ki lahko povzročijo zasoplost ali oteklost gležnjev
White, round, flat faced tablets debossed with “OG30” on one side.
bele, okrogle, ploske tablete z natisom "OG30" na eni strani.
The pharmacokinetics of cilostazol and its metabolites were not significantly affected by age or gender in healthy subjects aged between 50-80 years.
Pri zdravih osebah, starih med 50-80, starost ali spol nimata bistvenega vpliva na farmakokinetiko cilostazola in njegovih presnovkov.
Based on these data, the recommended dose of cilostazol is 50 mg bid in the presence of omeprazole.
Na podlagi teh podatkov je priporočeni odmerek cilostazola 50 mg dvakrat na dan v prisotnosti omeprazola.
produced a reduction in triglycerides of 0.33 mmol/l (15%) and an increase in HDL-cholesterol of 0.10 mmol/l (10%).
Po 12 tednih je v primerjavi s placebom <zdravilo, ki vsebuje cilostazol>, 100 mg dvakrat na dan, povzročilo zmanjšanje trigliceridov za 0,33 mmol/l (15 %) in povečanje HDL-holesterola za 0,10 mmol/l (10 %).
HOW TO TAKE <CILOSTAZOL-CONTAINING MEDICINAL PRODUCT>
Kako jemati <zdravilo, ki vsebuje cilostazol>
No dose adjustment is necessary in patients with a creatinine clearance of > 25 ml/min.
Odmerka pri bolnikih z očistkom kreatinina > 25 ml/min ni treba prilagoditi.
The <Cilostazol-containing medicinal product> 100 mg tablet is a white, round, flat-faced tablet, debossed with “OG30” on one side.
<Zdravilo, ki vsebuje cilostazol>, 100 mg tablete, so bele, okrogle, ploske tablete z vtisom "OG30" na eni strani.
Very common side effects (affecting more than 1 in 10 people) headache abnormal stools diarrhoea
zelo pogosti neželeni učinki (prizadenejo lahko več kot 1 od 10 bolnikov)
Reduction of the dose to 50 mg twice daily is recommended in patients receiving medicines that strongly inhibit CYP3A4, for example some macrolides, azole antifungals, protease inhibitors, or medicines that strongly inhibit CYP2C19, for example omeprazole (see sections 4.4 and 4.5).
Pri bolnikih, ki prejemajo zdravila, ki močno zavirajo encim CYP3A4, na primer nekatere makrolide, azolne antimikotike, zaviralce proteaze ali zdravila, ki močno zavirajo encim CYP2C19, na primer omeprazol (glejte poglavji 4.4 in 4.5), se priporoča zmanjšanje odmerka na 50 mg dvakrat na dan.
Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitor excl. heparin.
Farmakoterapevtska skupina: Antitrombotiki, zaviralci agregacije trombocitov brez heparina oznaka ATC: B01AC
Cilostazol is a PDE III inhibitor with antiplatelet activity.
Cilostazol je zaviralec PDE III s protitrombocitnim delovanjem.
METHOD AND ROUTE(S) OF ADMINISTRATION
POSTOPEK IN POT(I) UPORABE ZDRAVILA za peroralno uporabo
There are no data in patients with moderate to severe hepatic impairment and since cilostazol is extensively metabolised by hepatic enzymes, the medicine must not be used in such patients (see section 4.3).
Ker se cilostazol obsežno presnavlja z jetrnimi encimi, ga ti bolniki ne smejo jemati (glejte poglavje 4.3).
In this leaflet:
Pogostnosti ustrezajo:
QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains 50 mg of cilostazol.
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena tableta vsebuje 50 mg cilostazola.
The dehydro metabolite and 4'-transhydroxy metabolite are 97.4% and 66% protein bound respectively.
Na beljakovine je vezanega 97,4 % presnovka dehidro in 66 % presnovka 4'-trans-hidroksi.
The other ingredients are maize starch, microcrystalline cellulose, carmellose calcium, hypromellose and magnesium stearate.
• Druge sestavine zdravila so koruzni škrob, mikrokristalna celuloza, kalcijev karmelozat,
SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET
PRILOGA III POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA OZNAČEVANJE IN NAVODILO ZA UPORABO
In rats dosed during pregnancy, foetal weights were decreased.
Pri brejih podganah je dajanje zdravila povzročilo zmanjšanje telesne mase zarodka.
if you have persistent chest pain at rest, or have had a “heart attack” or any heart surgery in the last six months if you have now or previously suffered from blackouts due to heart disease, or any severe disturbances of the heart beat.
• če imate med mirovanjem v prsnem košu stalno bolečino ste imeli "srčni napad" ali poseg na srcu v zadnjih šestih mesecih
Caution is advised when cilostazol is co-administered with CYP3A4 substrates with a narrow therapeutic index (e.g., cisapride, halofantrine, pimozide, ergot derivates).
Pri sočasnem dajanju cilostazola s substrati CYP3A4 z ozkim terapevtskim indeksom (npr. cisaprid, halofantrin, pimozid, derivati ergota) je potrebna previdnost.
Maize starch, microcrystalline cellulose, carmellose calcium, hypromellose and magnesium stearate.
6.1 Seznam pomožnih snovi koruzni škorb, mikrokristalna celuloza, kalcijev karmelozat, hipromeloza in magnezijev stearat [Izpolni država članica]
Interstitial pneumonia
• pljučnica
Musculoskeletal, connective tissue and bone disorders
Bolezni mišično-skeletnega sistema in vezivnega tkiva občasni mialgija
One tablet contains 100 mg cilostazol.
Ena tableta vsebuje 100 mg cilostazola.
Based on AUC, the overall pharmacological activity of cilostazol increases 35% when co-administered with ketoconazole.
Na podlagi AUC se je skupna farmakološka dejavnost cilostazola povečala za 35 % pri sočasni uporabi s ketokonazolom.
One tablet contains 50 mg cilostazol.
Ena tableta vsebuje 50 mg cilostazola.
Inhibitors of platelet aggregation
Zaviranje agregacije trombocitov
The transfer of cilostazol to breast milk has been reported in animal studies.
Iz študij pri živalih poročajo o prehajanju cilostazola v materino mleko.
Cytochrome P-450 (CYP) enzyme inhibitors
Zaviralci encima citokroma P-450 (CYP)
Administration of cilostazol with omeprazole (an inhibitor of CYP2C19) increased the AUC of cilostazol by 22%, accompanied by a 68% increase in the AUC of the dehydro metabolite and a decrease of 36% in the AUC of the 4`-trans hydroxy metabolite.
Dajanje cilostazola z omeprazolom (zaviralec CYP2C19) je povečalo AUC cilostazola za 22 %, kar je spremljalo 68-odstotno povečanje AUC presnovka dehidro in 36-odstotno zmanjšanje AUC presnovka 4`-trans hidroksi.
No dosage adjustment is necessary in patients with mild hepatic disease.
Pri bolnikih z blago boleznijo jeter ni treba prilagoditi odmerka.
Ear and labyrinth disorders Unknown
Ušesne bolezni, vključno z motnjami labirinta neznana tinitus
Based on AUC, the overall pharmacological activity increases by 47% when co-administered with omeprazole.
Na podlagi AUC se je skupna farmakološka dejavnost pri sočasnem dajanju z omeprazolom povečala za 47 %.
Administration of cilostazol with diltiazem (a weak inhibitor of CYP3A4) resulted in an increase in the AUC of cilostazol of 44%, accompanied by a 4% increase in AUC of the dehydro metabolite and a 43% increase in the AUC of the 4`-trans-hydroxy metabolite.
Dajanje cilostazola z diltiazemom (šibek zaviralec CYP3A4) je povzročilo povečanje AUC cilostazola za 44 %, kar je spremljalo 4-odstotno povečanje AUC presnovka dehidro in 43-odstotno povečanje AUC presnovka 4`-trans-hidroksi.